ANONDITA MEDICARE LTD
NNSE:ANOND_RE170.00
INR
- -
- -
ISIN
INE0VTV20012
Return %
Stock
S&P 500
1Y
- -
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Anupam Ghosh
- Sector
- Producer manufacturing
- Industry
- Miscellaneous manufacturing
- Address
- Noida India
- Website
- anonditamedicare.com
- Similar Companies
- Business
- Anondita Medicare Limited is an India-based healthcare and sexual wellness manufacturing company primarily engaged in the development, production, marketing, and distribution of latex contraceptives and medical barrier products. Tracing its operational origins to 1999 and incorporated in its present corporate form in 2024, the company is headquartered in Noida, Uttar Pradesh, India, with its registered office in New Delhi. The company operates through two core business divisions, Sexual Wellness and Medical Healthcare, offering a comprehensive portfolio of products and services comprising: male latex condoms marketed under its flagship brand COBRA in plain, ultra-thin, ribbed, dotted, contoured, and multi-textured variations across fruit and confectionery flavors such as strawberry, chocolate, mint, butterscotch, coffee, and bubblegum; specialized female latex condoms; surgical gloves and medical examination gloves; personal protective equipment including 3-ply surgical face masks; and original equipment manufacturing (OEM), private-label packaging, and contract manufacturing services for retail pharmaceutical distributors, non-governmental organizations, and national public health programs. The company distributes its products domestically across retail, wholesale, and government channels, while exporting to international markets across Southeast Asia, Africa, and the Middle East. Recent operational and corporate developments include the completion of its Initial Public Offering (IPO) and public listing on the National Stock Exchange of India (NSE) in August 2025; a 75 crore INR phased capacity expansion project at its Noida production facility approved in 2026 to add 1,360 million pieces per annum; qualification under the South African national government Transversal Contract RT75-2025 along with a 43.14 crore INR export supply order from Supra Healthcare Johannesburg (Pty) Ltd; multiple major domestic procurement contract wins from the Central Medical Services Society (CMSS) under national health and family planning initiatives; the operational rollout of automated female condom manufacturing lines; and a 91.01 crore INR rights issue launched in September 2026 to fund working capital and ongoing infrastructure expansion.